Edition:
India

AC Immune SA (ACIU.OQ)

ACIU.OQ on NASDAQ Stock Exchange Global Market

13.77USD
13 Jul 2018
Change (% chg)

$-1.13 (-7.58%)
Prev Close
$14.90
Open
$14.99
Day's High
$14.99
Day's Low
$13.04
Volume
33,359
Avg. Vol
22,995
52-wk High
$16.32
52-wk Low
$6.24

Latest Key Developments (Source: Significant Developments)

AC Immune Reports Q1 Revenue CHF 1.5 Million
Wednesday, 2 May 2018 

May 2 (Reuters) - AC Immune SA ::AC IMMUNE REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND CORPORATE UPDATE.Q1 REVENUE CHF 1.5 MILLION.Q1 REVENUE VIEW CHF 2 MILLION -- THOMSON REUTERS I/B/E/S.QTRLY NON-IFRS EPS LOSS CHF 0.19.  Full Article

AC Immune SA reports quarterly ‍loss per share CHF 0.15
Monday, 13 Nov 2017 

Nov 13 (Reuters) - AC Immune SA ::AC Immune SA reports third quarter 2017 financial results and corporate update.AC Immune SA qtrly ‍loss per share CHF 0.15 .Says qtrly adjusted loss per share CHF ‍0.16​.  Full Article

AC Immune to get milestone payment for Alzheimer drug
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - AC Immune Ltd :Says to receive milestone payment for anti-tau antibody moving into phase 2 trial for Alzheimer's disease ‍​.Says upon the dosing of the first patient in the phase 2 clinical trial, AC Immune becomes eligible to receive a milestone payment of CHF 14 million, which is expected to be paid in the fourth quarter of 2017‍​.Says this will be the third milestone payment under the 2012 strategic collaboration and licensing agreement with Genentech.  Full Article

AC Immune SA to receive milestone payment for anti-tau antibody moving into phase 2 trial for alzheimer's disease
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Ac Immune Ltd :AC Immune SA to receive milestone payment for anti-tau antibody moving into phase 2 trial for Alzheimer's Disease.Ac Immune - ‍upon dosing of first patient in phase 2 trial of RO7105705​, co becomes eligible to get milestone payment of CHF 14 million, expected in Q4 2017.  Full Article

Essex Bio-Technology enters research project deal with AC Immune
Monday, 22 May 2017 

May 22 (Reuters) - Essex Bio-technology Ltd <1061.HK>:Company entered into research project agreement with ACI.Deal to collaborate in pre-clinical and clinical co-development of novel biological therapeutic to treat neurodegenerative diseases.  Full Article

AC Immune shares open at $14.11 in debut, above IPO price of $11 per share
Friday, 23 Sep 2016 

: AC Immune shares open at $14.11 in debut, above IPO price of $11.0 per share Further company coverage: [ACIU.O] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article